ALX Oncology (NASDAQ: ALXO)
$1.85
(-0.5%)
-$0.01
Price as of January 8, 2025, 4:00 p.m. ET
ALX Oncology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
ALX Oncology Company Info
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.
News & Analysis
Featured Article
Why ALX Oncology Stock Is Skyrocketing Today
Investors are cheering the immuno-oncology company's latest clinical trial results.
Keith Speights | Oct 3, 2023
Featured Article
Why Shares of ALX Oncology Holdings Fell Thursday
Several company executives sold shares of the stock.
Jim Halley | Jul 6, 2023
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.